BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to…
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to…
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline…
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline…
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment…
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment…
NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo”…
NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo”…
Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration NASH disease education…
Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration NASH disease education…
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — LifeSci Consulting, a boutique strategy consulting and…
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — LifeSci Consulting, a boutique strategy consulting and…
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from…
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from…
BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…
FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…
– Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01…
– Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01…
– Grace Breeding’s WDS, a proprietary and environmentally friendly formula to counteract crop climate stress,…